Abstract
The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Current Enzyme Inhibition
Title: ACE2; an ACE up the Sleeve?
Volume: 1 Issue: 1
Author(s): M. C. Thomas and C. Tikellis
Affiliation:
Keywords: ace2, renin-angiotensin system, angiotensin II, angiotensin, hypertension, diabetes, renal impairment, sars
Abstract: The traditional linear model of the RAS has now been replaced by a dynamic system than includes a number of new components. Among them the angiotensin converting enzyme type 2 has recently become recognized as an important homeostatic factor and counterbalance to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function. However, ACE2 also has a number of important independent actions as evidence by its differential distribution in both development and in adult tissues. Studies from knockout mice suggest that ACE2 is involved in both cardiac and renal development. ACE2 is also involved in a number of disease processes, most notably ACE2 has been reported recently to be the functional receptor for the severe acute respiratory syndrome (SARS) coronavirus. A reduction in ACE2 in diabetes may also contribute to endorgan damage. ACE2 may also have important functional consequences in heart failure and pre-eclampsia. In this context, selective inhibitors of ACE2 will provide important tools for exploring the physiology and pathology of the enzyme in both heath and disease states.
Export Options
About this article
Cite this article as:
Thomas C. M. and Tikellis C., ACE2; an ACE up the Sleeve?, Current Enzyme Inhibition 2005; 1 (1) . https://dx.doi.org/10.2174/1573408052952739
DOI https://dx.doi.org/10.2174/1573408052952739 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Cardiac Telocytes
Current Stem Cell Research & Therapy Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure
Current Drug Metabolism Fluid and Electrolyte Disorders in the Newborn: Sodium and Potassium
Current Pediatric Reviews Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Heme Oxygenase System and Hypertension: A Comprehensive Insight
Current Pharmaceutical Design Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Immunomodulatory Effect of Cytokines in the Differentiation of Mesenchymal Stem Cells: A Review
Current Stem Cell Research & Therapy Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design